Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PLx Pharma Inc. to Present at Upcoming Healthcare Industry Conferences

06/09/2021 | 04:30pm EDT

SPARTA, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present virtually at two upcoming healthcare conferences as follows:

The JMP Securities Life Sciences Conference:
  
Date:Wednesday, June 16, 2021
  
Time:12:30PM Eastern Time
  
Webcast Link:https://wsw.com/webcast/jmp49/plxp/1710800
  
The Raymond James Human Health Innovation Conference 2021:
  
Date:Monday, June 21, 2021
  
Time:2:40PM Eastern Time
  
Webcast Link:https://kvgo.com/rj-health/plx-pharma-inc-june-2021

The presentations will be webcast live at the aforementioned times, and archived for 30 days thereafter, via the Company’s website at www.plxpharma.com, under the ‘Investors Relations’ Section.

About VAZALORE

VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

About PLx Pharma Inc. 

PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com


Primary Logo


ę GlobeNewswire 2021
All news about PLX PHARMA INC.
07/27PLX PHARMA : to Make Vazalore Available in Over 2,400 Rite Aid Stores in August
MT
07/26PLX PHARMA : VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
AQ
07/26PLx Pharma Inc.’s VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
CI
07/22PLX PHARMA : to Discuss 2021 Second Quarter Financial Results on August 6, 2021 ..
AQ
07/20AFTER HOURS WATCH LIST SCORECARD : Plxp, ppg, ardx
MT
07/20PLx Shares Rise as Walgreens Set to Carry Vazalore in Stores
DJ
07/20SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Tuesday
MT
07/20PLX PHARMA : JMP Securities Adjusts PLx Pharma's Price Target to $21 From $12, K..
MT
07/19MT NEWSWIRES AFTER HOURS WATCH LIST : Plxp, ppg, ardx
MT
07/19PLX PHARMA : Shares Up 15% on VAZALORE's Walgreens Launch
MT
More news
Financials (USD)
Sales 2021 5,73 M - -
Net income 2021 -27,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -14,7x
Yield 2021 -
Capitalization 445 M 445 M -
Capi. / Sales 2021 77,7x
Capi. / Sales 2022 16,8x
Nbr of Employees 10
Free-Float 81,8%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 19,38 $
Average target price 21,50 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.251.09%445
GILEAD SCIENCES, INC.18.31%86 451
BIONTECH SE248.38%68 592
WUXI APPTEC CO., LTD.28.80%64 659
REGENERON PHARMACEUTICALS20.26%60 167
VERTEX PHARMACEUTICALS-14.17%52 511